Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial

Micro-Abstract Cisplatin with pemetrexed followed by maintenance pemetrexed and carboplatin with paclitaxel and bevacizumab followed by maintenance bevacizumab, standard first-line therapy for advanced nonsquamous non–small-cell lung cancer, were compared. Quality of life (QoL) at 12 weeks of mainte...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lung cancer 2015-07, Vol.16 (4), p.262-273
Hauptverfasser:	Galetta, Domenico, Cinieri, Saverio, Pisconti, Salvatore, Gebbia, Vittorio, Morabito, Alessandro, Borsellino, Nicola, Maiello, Evaristo, Febbraro, Antonio, Catino, Annamaria, Rizzo, Pietro, Montrone, Michele, Misino, Andrea, Logroscino, Antonio, Rizzi, Daniele, Di Maio, Massimo, Colucci, Giuseppe
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Advanced NSCLC Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab - administration & dosage Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Cisplatin - administration & dosage EQ5D Female Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Middle Aged Neoplasm Staging Paclitaxel - administration & dosage Pemetrexed - administration & dosage Pulmonary/Respiratory Quality of Life Symptom palliation Treatment choice Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract Cisplatin with pemetrexed followed by maintenance pemetrexed and carboplatin with paclitaxel and bevacizumab followed by maintenance bevacizumab, standard first-line therapy for advanced nonsquamous non–small-cell lung cancer, were compared. Quality of life (QoL) at 12 weeks of maintenance, measured using the EuroQoL 5 Dimensions (EQ5D) Index and EQ5D-visual analogue scale, was the primary end point. QoL did not differ between these regimens. Comorbidities and other factors should help in deciding first-line treatment.
ISSN:	1525-7304 1938-0690
DOI:	10.1016/j.cllc.2014.12.002